Novel antimalarial drugs
By developing tetrahydroisoquinoline derivatives with higher metabolic stability, the problems of drug resistance and poor adherence to multiple-dose treatments in existing antimalarial drugs have been solved, achieving the antimalarial effect of low-dose single-dose treatment.
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
- Filing Date
- 2021-04-08
- Publication Date
- 2026-07-01
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing antimalarial drugs suffer from drug resistance issues, and existing candidate drugs are not effective in single-dose treatment, making it difficult to meet the treatment requirements of the World Health Organization. Furthermore, multiple-dose treatment leads to poor patient compliance.
A series of tetrahydroisoquinoline derivatives were developed, and by optimizing their inhibitory effect on parasite ATP4' enzyme, the metabolic stability of the drug was improved. The effective dose for single-dose treatment is expected to be less than 500 mg, reducing the frequency of administration.
Tetrahydroisoquinoline derivatives have shown significant antimalarial activity, improved metabolic stability, and are expected to be effective with single-dose treatment, thus enhancing patient compliance.
Smart Images
Figure 0007883235000059 
Figure 0007883235000060 
Figure 0007883235000061